- |||||||||| risedronate delayed-release / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date, Surgery, Bariatric surgery: WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (clinicaltrials.gov) - Mar 2, 2023 P3, N=200, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Apr 2027 | Trial primary completion date: Dec 2024 --> Apr 2027
- |||||||||| risedronate delayed-release / Generic mfg.
Trial completion date, Trial primary completion date, Surgery, Bariatric surgery: WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (clinicaltrials.gov) - Nov 29, 2022 P3, N=200, Not yet recruiting, Not yet recruiting --> Recruiting | Trial completion date: Dec 2024 --> Apr 2027 | Trial primary completion date: Dec 2024 --> Apr 2027 Trial completion date: Dec 2026 --> Dec 2024 | Trial primary completion date: Dec 2026 --> Dec 2024
- |||||||||| risedronate delayed-release / Generic mfg.
Trial completion date, Trial primary completion date: Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT (clinicaltrials.gov) - Sep 15, 2022 P2, N=84, Active, not recruiting, Trial completion date: Dec 2026 --> Dec 2024 | Trial primary completion date: Dec 2026 --> Dec 2024 Trial completion date: Aug 2023 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Mar 2022
- |||||||||| risedronate delayed-release / Generic mfg.
Trial completion date, Trial primary completion date, Surgery, Bariatric surgery: WE RISE U01: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (clinicaltrials.gov) - Jun 1, 2022 P3, N=200, Not yet recruiting, Trial completion date: Aug 2023 --> Mar 2023 | Trial primary completion date: Aug 2022 --> Mar 2022 Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026
- |||||||||| risedronate delayed-release / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT (clinicaltrials.gov) - Mar 2, 2022 P2, N=84, Active, not recruiting, Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Dec 2026 Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Aug 2023 | Trial primary completion date: Aug 2023 --> Aug 2022
- |||||||||| risedronate / Generic mfg.
Journal: History of risedronate. (Pubmed Central) - Jun 22, 2021 which never actively promoted the drug. Generic forms of risedronate were introduced into the United States in 2015 but are rarely used, although several generic forms are actively marketed in other countries.
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Exome Sequencing for Atypical Femoral Fractures (clinicaltrials.gov) - Dec 31, 2018 P=N/A, N=38, Completed, Initiation date: May 2019 --> Jul 2019 Enrolling by invitation --> Completed | Trial completion date: Jun 2018 --> Mar 2018 | Trial primary completion date: Jun 2018 --> Mar 2018
- |||||||||| Trial primary completion date: Exome Sequencing for Atypical Femoral Fractures (clinicaltrials.gov) - Nov 9, 2017
P=N/A, N=36, Enrolling by invitation, Enrolling by invitation --> Completed | Trial completion date: Jun 2018 --> Mar 2018 | Trial primary completion date: Jun 2018 --> Mar 2018 Trial primary completion date: Apr 2017 --> Jun 2018
|